Company / PP&E (Net)
Vertex Pharmaceuticals PP&E (Net) History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$758.1M
FY2019
5-year range
-
FY2016-FY2019
Trend
-6.6%
vs FY2018
Sector context
#19 of 193
Health Care
What the data says
Among 193 Health Care companies, Vertex Pharmaceuticals is in the top 10% for pp&e (net). Declined from $789M to $758M over the past 2 years.
Based on SEC 10-K filings.
$758M in FY2019 with a 3-year CAGR of +2.8%. Top quartile in the Health Care sector.
Declined from $789M to $758M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +2.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 193This company $758.1M Sector average $777.6M
▼
-2.5% below sector average
Key checks
Key Insights
- 3-year CAGR of +2.8%, indicating consistent growth.
- In FY2019, pp&e (net) decreased 6.6% year-over-year.
- Ranks #19 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $758.1M | -6.6% |
| FY2018 | $812.0M | +2.9% |
| FY2017 | $789.4M | +13.0% |
| FY2016 | $698.4M | +0.1% |
As of FY2019 · SEC 10-K · Updated Mar 17, 2026